Silencing of immune activation with methotrexate in patients with COVID-19

It is becoming apparent that patients with COVID-19 are developing a wide variety of autoimmune syndromes many of which involve the nervous system (Table 1). These syndromes most often occur when patients are recovering from the acute viral symptoms. Even in patients with active infection in the lungs, the inflammatory response to the viral infection can be overwhelming in some which is thought to be the major cause of acute respiratory distress syndrome or the viral pneumonia [1,2]. The inflammation is also thought to mediate a hypercoagulable state leading to thromboses in multiple blood vessels and organ systems including the brain [3,4].

from Journal of the Neurological Sciences https://ift.tt/3gh37Qu